Clinical Trial Update: The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating whether oral diindolylmethane (DIM) supplementation can increase BRCA1 protein production in BRCA1 mutation carriers with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Diindolylmethane (DIM) (Diindolylmethane)

Snippet

Sponsor: Women's College Hospital | Conditions: Breast Cancer | Phase 1 | Status: UNKNOWN